| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ef308a4e9140a732cd9b25f05974fff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30942758050206c633653d0ab178a202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2988460247a9b2f538f468d09b82f366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41f3512accd7696fcf24a897996ffc33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5ffa3f9d6b87e15e0a1551fb129b531 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate |
1999-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c784d89be0fcd17d2c730f932fba3e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70a40663afc4308e5422fb01eb71629b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbc3fb6fefccb62d790b65e21ca3994e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13778ec78a6dc155eea1e44a0859915f |
| publicationDate |
2000-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0006132-A3 |
| titleOfInvention |
Pharmaceutical formulations comprising beclomethasone dipropionate for the treatment of inflammatory bowel disease |
| abstract |
The invention relates to pharmaceutical formulations for the treatment of inflammatory bowel disease containing as active ingredient Beclomethasone dipropionate. A first aspect concerns a formulation in the form of stable and ready-to-use enema characterized in that the homogeneity of the active ingredient at low concentration (0.05 %) and fluidity of the suspension is optimal for promoting its retrograde progression and homogeneous distribution. A second aspect concerns gastro-resistant modified-release tablets whose composition has been optimized in order to control the release of the active ingredient in fluids at basic pH and low ionic strength. |
| priorityDate |
1998-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |